{ "instance": { "ea146254-6k_xtlbiopharma.htm ea146254ex99-2_xtlbiopharma.htm": { "axisCustom": 3, "axisStandard": 4, "contextCount": 82, "dts": { "calculationLink": { "local": [ "xtlb-20210630_cal.xml" ] }, "definitionLink": { "local": [ "xtlb-20210630_def.xml" ] }, "inline": { "local": [ "ea146254-6k_xtlbiopharma.htm", "ea146254ex99-2_xtlbiopharma.htm" ] }, "labelLink": { "local": [ "xtlb-20210630_lab.xml", "doc_full_ifrs-en_2021-03-24.xml", "us-gaap-doc-2021-01-31.xml" ] }, "presentationLink": { "local": [ "xtlb-20210630_pre.xml" ] }, "referenceLink": { "local": [ "ref_ifrs_1_2021-03-24.xml", "ref_sic_29_2021-03-24.xml", "ref_ias_12_2021-03-24.xml", "ref_ifrs_5_2021-03-24.xml", "ref_ifric_5_2021-03-24.xml", "ref_ias_2_2021-03-24.xml", "ref_ifrs_3_2021-03-24.xml", "ref_ias_38_2021-03-24.xml", "ref_ias_34_2021-03-24.xml", "ref_ifrs_17_2021-03-24.xml", "ref_ias_24_2021-03-24.xml", "ref_ias_29_2021-03-24.xml", "ref_ias_27_2021-03-24.xml", "ref_ifrs_16_2021-03-24.xml", "ref_ias_10_2021-03-24.xml", "ref_ias_37_2021-03-24.xml", "ref_ifrs_7_2021-03-24.xml", "ref_ias_36_2021-03-24.xml", "us-gaap-ref-2021-01-31.xml", "ref_ias_20_2021-03-24.xml", "ref_ifric_2_2021-03-24.xml", "ref_ifrs_13_2021-03-24.xml", "ref_ias_40_2021-03-24.xml", "ref_ifrs_15_2021-03-24.xml", "ref_ifrs_6_2021-03-24.xml", "ref_ias_16_2021-03-24.xml", "ref_ias_7_2021-03-24.xml", "ref_ias_1_2021-03-24.xml", "ref_ifrs_12_2021-03-24.xml", "ref_ias_23_2021-03-24.xml", "ref_ias_8_2021-03-24.xml", "ref_ifrs_4_2021-03-24.xml", "ref_ias_41_2021-03-24.xml", "ref_ifrs_2_2021-03-24.xml", "ref_ifrs_14_2021-03-24.xml", "ref_ias_19_2021-03-24.xml", "ref_ias_33_2021-03-24.xml", "ref_ias_26_2021-03-24.xml", "ref_ifrs_8_2021-03-24.xml", "ref_ias_21_2021-03-24.xml" ] }, "schema": { "local": [ "xtlb-20210630.xsd", "xbrl-linkbase-2003-12-31.xsd", "xl-2003-12-31.xsd", "xlink-2003-12-31.xsd", "net-2009-12-16.xsd", "negated-2009-12-16.xsd", "full_ifrs-cor_2021-03-24.xsd", "xbrl-instance-2003-12-31.xsd", "nonNumeric-2009-12-16.xsd", "numeric-2009-12-16.xsd", "xbrldt-2005.xsd", "dei-2021.xsd", "types.xsd", "us-gaap-2021-01-31.xsd", "extensible-enumerations-2.0.xsd", "ref-2006-02-27.xsd", "us-types-2021-01-31.xsd", "srt-types-2021-01-31.xsd", "srt-2021-01-31.xsd", "country-2021.xsd", "srt-roles-2021-01-31.xsd", "us-roles-2021-01-31.xsd", "sic-2021.xsd", "reference-2009-12-16.xsd", "dei-2021_doc.xsd", "dei-2021_ref.xsd", "us-parts-codification-2021-01-31.xsd" ] } }, "elementCount": 192, "entityCount": 1, "hidden": { "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full": 36, "http://xbrl.sec.gov/dei/2021": 15, "http://xtlb.com/20210630": 2, "total": 53 }, "keyCustom": 41, "keyStandard": 153, "memberCustom": 8, "memberStandard": 6, "nsprefix": "xtlb", "nsuri": "http://xtlb.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "ea146254-6k_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://xtlb.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "ea146254-6k_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:ExplanationOfFinancialEffectOfNonadjustingEventAfterReportingPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Significant Events During The Period", "role": "http://xtlb.com/role/SignificantEventsDuringThePeriod", "shortName": "Significant Events During The Period", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:ExplanationOfFinancialEffectOfNonadjustingEventAfterReportingPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfRestatementtextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Restatement", "role": "http://xtlb.com/role/Restatement", "shortName": "Restatement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfRestatementtextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfMarketableSecuritiesExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Marketable Securities \u2013 InterCure Ltd", "role": "http://xtlb.com/role/MarketableSecuritiesInterCureLtd", "shortName": "Marketable Securities \u2013 InterCure Ltd", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfMarketableSecuritiesExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:WarrantsAtFairValueOfExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Warrants", "role": "http://xtlb.com/role/Warrants", "shortName": "Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:WarrantsAtFairValueOfExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Transactions With Related Parties", "role": "http://xtlb.com/role/TransactionsWithRelatedParties", "shortName": "Transactions With Related Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Subsequent Events", "role": "http://xtlb.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfConsolidatedStatementOfComprehensiveIncomelossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Restatement (Tables)", "role": "http://xtlb.com/role/RestatementTables", "shortName": "Restatement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:DisclosureOfConsolidatedStatementOfComprehensiveIncomelossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Marketable Securities \u2013 InterCure Ltd (Tables)", "role": "http://xtlb.com/role/MarketableSecuritiesInterCureLtdTables", "shortName": "Marketable Securities \u2013 InterCure Ltd (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Warrants (Tables)", "role": "http://xtlb.com/role/WarrantsTables", "shortName": "Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "xtlb:ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Transactions With Related Parties (Tables)", "role": "http://xtlb.com/role/TransactionsWithRelatedPartiesTables", "shortName": "Transactions With Related Parties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c1", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Consolidated Statements of Financial Position (Unaudited)", "role": "http://xtlb.com/role/ConsolidatedBalanceSheet", "shortName": "Condensed Consolidated Statements of Financial Position (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c1", "decimals": "-3", "lang": null, "name": "xtlb:CurrentMarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c53", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinanceIncomeCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Restatement (Details) - Schedule of impact on the consolidated statement of comprehensive income (loss)", "role": "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementofcomprehensiveincomelossTable", "shortName": "Restatement (Details) - Schedule of impact on the consolidated statement of comprehensive income (loss)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c53", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinanceIncomeCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c56", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AdditionalPaidinCapital", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Restatement (Details) - Schedule of impact on the consolidated statements of financial position", "role": "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementsoffinancialpositionTable", "shortName": "Restatement (Details) - Schedule of impact on the consolidated statements of financial position", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:DisclosureOfDetailedInformationAboutConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c56", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AdditionalPaidinCapital", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c59", "decimals": "4", "first": true, "lang": null, "name": "xtlb:PercentageOfHoldingShare", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Marketable Securities \u2013 InterCure Ltd (Details)", "role": "http://xtlb.com/role/MarketableSecuritiesInterCureLtdDetails", "shortName": "Marketable Securities \u2013 InterCure Ltd (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c59", "decimals": "4", "first": true, "lang": null, "name": "xtlb:PercentageOfHoldingShare", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Marketable Securities \u2013 InterCure Ltd (Details) - Schedule of financial instruments", "role": "http://xtlb.com/role/ScheduleoffinancialinstrumentsTable", "shortName": "Marketable Securities \u2013 InterCure Ltd (Details) - Schedule of financial instruments", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c60", "decimals": "-3", "first": true, "lang": null, "name": "xtlb:GrossFundRaised", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Warrants (Details)", "role": "http://xtlb.com/role/WarrantsDetails", "shortName": "Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c60", "decimals": "-3", "first": true, "lang": null, "name": "xtlb:GrossFundRaised", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "xtlb:ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c59", "decimals": "4", "first": true, "lang": null, "name": "xtlb:DescriptionOfRiskFreeInterestsRateShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Warrants (Details) - Schedule of warrants valuation assumptions of investors' warrants", "role": "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable", "shortName": "Warrants (Details) - Schedule of warrants valuation assumptions of investors' warrants", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "xtlb:ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c59", "decimals": "4", "first": true, "lang": null, "name": "xtlb:DescriptionOfRiskFreeInterestsRateShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfTheOutstandingWarrantsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c1", "decimals": "INF", "first": true, "lang": null, "name": "xtlb:WarrantsOutstandingToPurchaseADSs", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Warrants (Details) - Schedule of outstanding warrants", "role": "http://xtlb.com/role/ScheduleofoutstandingwarrantsTable", "shortName": "Warrants (Details) - Schedule of outstanding warrants", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "xtlb:ScheduleOfTheOutstandingWarrantsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c1", "decimals": "INF", "first": true, "lang": null, "name": "xtlb:WarrantsOutstandingToPurchaseADSs", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": "4", "first": true, "lang": null, "name": "xtlb:ProportionOfOwnershipInterestInInterCureLtd", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Transactions With Related Parties (Details)", "role": "http://xtlb.com/role/TransactionsWithRelatedPartiesDetails", "shortName": "Transactions With Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": "4", "first": true, "lang": null, "name": "xtlb:ProportionOfOwnershipInterestInInterCureLtd", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:BenefitsPaidOrPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Transactions With Related Parties (Details) - Schedule of compensation to key management personnel for employee services", "role": "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable", "shortName": "Transactions With Related Parties (Details) - Schedule of compensation to key management personnel for employee services", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:BenefitsPaidOrPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c79", "decimals": "INF", "first": true, "lang": null, "name": "xtlb:NumberOfInvestors", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Subsequent Events (Details)", "role": "http://xtlb.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c79", "decimals": "INF", "first": true, "lang": null, "name": "xtlb:NumberOfInvestors", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c1", "decimals": "1", "first": true, "lang": null, "name": "ifrs-full:ParValuePerShare", "reportCount": 1, "unique": true, "unitRef": "ilsPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Consolidated Statements of Financial Position (Unaudited) (Parentheticals)", "role": "http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Condensed Consolidated Statements of Financial Position (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c1", "decimals": "1", "first": true, "lang": null, "name": "ifrs-full:ParValuePerShare", "reportCount": 1, "unique": true, "unitRef": "ilsPershares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "role": "http://xtlb.com/role/ConsolidatedIncomeStatement", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c18", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Statements of Changes in Equity (Unaudited)", "role": "http://xtlb.com/role/ShareholdersEquityType2or3", "shortName": "Condensed Statements of Changes in Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c18", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://xtlb.com/role/ConsolidatedCashFlow", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": "-3", "lang": null, "name": "xtlb:AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralHedgeAccountingExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - General", "role": "http://xtlb.com/role/General", "shortName": "General", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralHedgeAccountingExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Basis of Preparation of the Unaudited Interim Consolidated Financial Statements", "role": "http://xtlb.com/role/BasisofPreparationoftheUnauditedInterimConsolidatedFinancialStatements", "shortName": "Basis of Preparation of the Unaudited Interim Consolidated Financial Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Significant Accounting Policies", "role": "http://xtlb.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea146254ex99-2_xtlbiopharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 14, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xtlb.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "ifrs-full_AdditionalPaidinCapital": { "auth_ref": [ "r13" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders." } }, "en-us": { "role": { "label": "Additional paid-in capital", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidinCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet", "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementsoffinancialpositionTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "auth_ref": [ "r41" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade accounts payable", "terseLabel": "Increase (decrease) in other accounts payable" } } }, "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLoss": { "auth_ref": [ "r43" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments to reconcile profit (loss)", "totalLabel": "Net operating asset and liability" } } }, "localname": "AdjustmentsForReconcileProfitLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForSharebasedPayments": { "auth_ref": [ "r42" ], "calculation": { "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable": { "order": 3.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Share-based payments" } } }, "localname": "AdjustmentsForSharebasedPayments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r13", "r59", "r60", "r61", "r70", "r72" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_BenefitsPaidOrPayable": { "auth_ref": [ "r32" ], "calculation": { "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable": { "order": 1.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of benefits paid or payable for retirement benefit plans." } }, "en-us": { "role": { "label": "Benefits paid or payable", "terseLabel": "Salaries, management and consulting fees and other short-term benefits" } } }, "localname": "BenefitsPaidOrPayable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BottomOfRangeMember": { "auth_ref": [ "r62", "r63", "r64", "r65", "r68", "r74" ], "lang": { "en": { "role": { "documentation": "This member stands for the bottom of a range." } }, "en-us": { "role": { "label": "Bottom of range [member]", "terseLabel": "Bottom of Range [Member]" } } }, "localname": "BottomOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "domainItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r12", "r47", "r58" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents at the end of the period", "periodStartLabel": "Cash and cash equivalents at the beginning of the period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet", "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r37", "r48" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "terseLabel": "Net cash provided by financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r37", "r48" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash from investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r37", "r48" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperations": { "auth_ref": [ "r43", "r49" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en": { "role": { "documentation": "The cash from (used in) the entity's operations." } }, "en-us": { "role": { "label": "Cash flows from (used in) operations", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "CashFlowsFromUsedInOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "auth_ref": [ "r30" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of related parties [axis]" } } }, "localname": "CategoriesOfRelatedPartiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/TransactionsWithRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r14", "r54", "r55" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } } }, "localname": "CurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "localname": "CurrentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": { "auth_ref": [ "r13" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]" } }, "en-us": { "role": { "label": "Current prepayments and other current assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "CurrentPrepaymentsAndOtherCurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationExpense": { "auth_ref": [ "r8" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives." } }, "en-us": { "role": { "label": "Depreciation expense", "terseLabel": "Depreciation" } } }, "localname": "DepreciationExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory": { "auth_ref": [ "r29" ], "lang": { "en": { "role": { "documentation": "The disclosure of amounts incurred by the entity for provision of key management personnel services that are provided by separate management entities. [Refer: Key management personnel of entity or parent [member]; Separate management entities [member]]" } }, "en-us": { "role": { "label": "Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [text block]", "terseLabel": "Schedule of compensation to key management personnel for employee services" } } }, "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/TransactionsWithRelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the basis used for the preparation of the financial statements." } }, "en-us": { "role": { "label": "Disclosure of basis of preparation of financial statements [text block]", "terseLabel": "BASIS OF PREPARATION OF THE UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS" } } }, "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/BasisofPreparationoftheUnauditedInterimConsolidatedFinancialStatements" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "auth_ref": [ "r66", "r67", "r68" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [text block]", "terseLabel": "Schedule of financial instruments" } } }, "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/MarketableSecuritiesInterCureLtdTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "auth_ref": [ "r27" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure of events after reporting period [text block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory": { "auth_ref": [ "r69" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for general hedge accounting." } }, "en-us": { "role": { "label": "Disclosure of general hedge accounting [text block]", "terseLabel": "GENERAL" } } }, "localname": "DisclosureOfGeneralHedgeAccountingExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/General" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [line items]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Abstract]" } } }, "localname": "DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "auth_ref": [ "r31" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for related parties." } }, "en-us": { "role": { "label": "Disclosure of related party [text block]", "terseLabel": "TRANSACTIONS WITH RELATED PARTIES" } } }, "localname": "DisclosureOfRelatedPartyExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/TransactionsWithRelatedParties" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for significant accounting policies applied by the entity." } }, "en-us": { "role": { "label": "Disclosure of significant accounting policies [text block]", "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "auth_ref": [ "r44", "r45" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Gains from exchange rate differences on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EmployeeBenefitsExpense": { "auth_ref": [ "r1", "r2", "r23" ], "calculation": { "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Employee benefits expense", "totalLabel": "Total compensation expense" } } }, "localname": "EmployeeBenefitsExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "auth_ref": [ "r30" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for related parties [member]" } } }, "localname": "EntitysTotalForRelatedPartiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/TransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r13", "r16", "r50", "r52", "r59", "r60", "r61" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Total equity", "totalLabel": "Total equity" } } }, "localname": "Equity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet", "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementsoffinancialpositionTable", "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:" } } }, "localname": "EquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r13" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total liabilities and equity" } } }, "localname": "EquityAndLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity and liabilities [abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "localname": "EquityAndLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } }, "en-us": { "role": { "label": "Equity [member]" } } }, "localname": "EquityMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": { "auth_ref": [ "r65" ], "lang": { "en": { "role": { "documentation": "The exercise price of outstanding share options." } }, "en-us": { "role": { "label": "Exercise price of outstanding share options", "terseLabel": "Exercise price, per share (in Dollars per share)" } } }, "localname": "ExercisePriceOfOutstandingShareOptions2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_ExplanationOfFinancialEffectOfNonadjustingEventAfterReportingPeriod": { "auth_ref": [ "r25" ], "lang": { "en": { "role": { "documentation": "The explanation of either an estimate of the financial effect of a non-adjusting event after the reporting period or a statement that such an estimate cannot be made." } }, "en-us": { "role": { "label": "Explanation of financial effect of non-adjusting event after reporting period [text block]", "terseLabel": "SIGNIFICANT EVENTS DURING THE PERIOD" } } }, "localname": "ExplanationOfFinancialEffectOfNonadjustingEventAfterReportingPeriod", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/SignificantEventsDuringThePeriod" ], "xbrltype": "textBlockItemType" }, "ifrs-full_FinanceIncomeCost": { "auth_ref": [ "r22" ], "calculation": { "http://xtlb.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income or cost associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance income (cost)", "terseLabel": "Finance income (expenses), net", "totalLabel": "Finance expenses, net" } } }, "localname": "FinanceIncomeCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement", "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementofcomprehensiveincomelossTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeneralAndAdministrativeExpense": { "auth_ref": [ "r8" ], "calculation": { "http://xtlb.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } }, "en-us": { "role": { "label": "General and administrative expense", "negatedLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "auth_ref": [ "r47" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "Decrease in cash and cash equivalents" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": { "auth_ref": [ "r5" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of warrants." } }, "en-us": { "role": { "label": "Increase (decrease) through exercise of warrants, equity", "terseLabel": "Exercise of warrants to ordinary shares" } } }, "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "auth_ref": [ "r4" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Share-based payment to employees and non-employees" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r10", "r35" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Intangible assets other than goodwill", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestReceivedClassifiedAsInvestingActivities": { "auth_ref": [ "r46" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from interest received, classified as investing activities." } }, "en-us": { "role": { "label": "Interest received, classified as investing activities", "terseLabel": "Interest from bank deposit" } } }, "localname": "InterestReceivedClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r16" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Issued capital", "terseLabel": "Share capital - ordinary shares of NIS 0.1 par value: authorized - June 30, 2021 (unaudited) and December 31, 2020 - 1,450,000,000 shares; issued and outstanding: June 30, 2021 (unaudited) 528,156,149,and December 31, 2020 - 514,205,799 (audited)" } } }, "localname": "IssuedCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Issued capital [member]", "terseLabel": "Share capital" } } }, "localname": "IssuedCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ifrs-full_IssuedCapitalOrdinaryShares": { "auth_ref": [ "r16" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]" } }, "en-us": { "role": { "label": "Issued capital, ordinary shares", "terseLabel": "Issued capital (in Dollars)" } } }, "localname": "IssuedCapitalOrdinaryShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": { "auth_ref": [ "r28" ], "calculation": { "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable": { "order": 2.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, post-employment benefits", "terseLabel": "Pension, post retirement and other benefits" } } }, "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "auth_ref": [ "r26" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } } }, "localname": "NonadjustingEventsAfterReportingPeriodAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r14", "r54", "r56" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "NON-CURRENT ASSETS:" } } }, "localname": "NoncurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentLiabilities": { "auth_ref": [ "r15", "r54", "r57" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Non-current liabilities", "terseLabel": "Non-current liabilities" } } }, "localname": "NoncurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementsoffinancialpositionTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NumberOfEmployees": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } }, "en-us": { "role": { "label": "Number of employees", "terseLabel": "Number of persons" } } }, "localname": "NumberOfEmployees", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofcompensationtokeymanagementpersonnelforemployeeservicesTable" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfSharesAuthorised": { "auth_ref": [ "r17" ], "lang": { "en": { "role": { "documentation": "The number of shares authorised." } }, "en-us": { "role": { "label": "Number of shares authorised", "terseLabel": "Ordinary shares, authorized" } } }, "localname": "NumberOfSharesAuthorised", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r5" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "Number of shares issued", "terseLabel": "Ordinary shares, issued" } } }, "localname": "NumberOfSharesIssued", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesOutstanding": { "auth_ref": [ "r19" ], "lang": { "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Number of shares outstanding", "terseLabel": "Ordinary shares, outstanding" } } }, "localname": "NumberOfSharesOutstanding", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "ifrs-full_OtherFinanceCost": { "auth_ref": [ "r8" ], "calculation": { "http://xtlb.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]" } }, "en-us": { "role": { "label": "Other finance cost", "negatedLabel": "Other finance expenses" } } }, "localname": "OtherFinanceCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherFinanceIncome": { "auth_ref": [ "r8" ], "calculation": { "http://xtlb.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]" } }, "en-us": { "role": { "label": "Other finance income", "terseLabel": "Other finance income" } } }, "localname": "OtherFinanceIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherNoncurrentFinancialAssets": { "auth_ref": [ "r11" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]" } }, "en-us": { "role": { "label": "Other non-current financial assets", "terseLabel": "Fixed assets, net" } } }, "localname": "OtherNoncurrentFinancialAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReserves": { "auth_ref": [ "r16" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } }, "en-us": { "role": { "label": "Other reserves", "terseLabel": "Reserve from transactions with non-controlling interests" } } }, "localname": "OtherReserves", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReservesMember": { "auth_ref": [ "r6", "r20" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]" } }, "en-us": { "role": { "label": "Other reserves [member]", "terseLabel": "Reserve from transactions with non-controlling interests" } } }, "localname": "OtherReservesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ifrs-full_ParValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en": { "role": { "documentation": "The nominal value per share." } }, "en-us": { "role": { "label": "Par value per share", "terseLabel": "Ordinary shares, par value (in New Shekels per share)" } } }, "localname": "ParValuePerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } }, "en-us": { "role": { "label": "Proceeds from exercise of warrants", "terseLabel": "Exercise of warrants" } } }, "localname": "ProceedsFromExerciseOfWarrants", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r3", "r21", "r40", "r51", "r53", "r54", "r70", "r71", "r73", "r75" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 }, "http://xtlb.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Profit (loss)", "netLabel": "Total comprehensive income (loss) for the year", "terseLabel": "Loss for the period", "totalLabel": "Total loss for the period", "verboseLabel": "Net loss for the period" } } }, "localname": "ProfitLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow", "http://xtlb.com/role/ConsolidatedIncomeStatement", "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementofcomprehensiveincomelossTable", "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r22", "r33" ], "calculation": { "http://xtlb.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Operating loss" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r38" ], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Purchase of property, plant and equipment, classified as investing activities", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RangeAxis": { "auth_ref": [ "r62", "r63", "r64", "r65", "r68", "r74" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Range [axis]" } } }, "localname": "RangeAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesMember": { "auth_ref": [ "r62", "r63", "r64", "r65", "r68", "r74" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } }, "en-us": { "role": { "label": "Ranges [member]" } } }, "localname": "RangesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "domainItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r36" ], "calculation": { "http://xtlb.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r16", "r24" ], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarnings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet", "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementsoffinancialpositionTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsMember": { "auth_ref": [ "r6", "r7" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings [member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Statement of changes in equity [line items]" } } }, "localname": "StatementOfChangesInEquityLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityTable": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } }, "en-us": { "role": { "label": "Statement of changes in equity [table]" } } }, "localname": "StatementOfChangesInEquityTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TopOfRangeMember": { "auth_ref": [ "r62", "r63", "r64", "r65", "r68", "r74" ], "lang": { "en": { "role": { "documentation": "This member stands for top of a range." } }, "en-us": { "role": { "label": "Top of range [member]", "terseLabel": "Top of Range [Member]" } } }, "localname": "TopOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "domainItemType" }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "auth_ref": [ "r65" ], "lang": { "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average remaining contractual life of outstanding share options", "terseLabel": "Contractual term life (in years)" } } }, "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "durationItemType" }, "ifrs-full_WeightedAverageShares": { "auth_ref": [ "r34" ], "lang": { "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Weighted average number of Ordinary Shares used in computing basic and diluted net loss per share (in Shares)" } } }, "localname": "WeightedAverageShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r78", "r79", "r80", "r81", "r82", "r83", "r84" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtlb.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r76", "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities \u2013 InterCure Ltd" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtlb.com/role/ScheduleoffinancialinstrumentsTable" ], "xbrltype": "monetaryItemType" }, "xtlb_AdjustmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AdjustmentsMember", "terseLabel": "Adjustments [Member]" } } }, "localname": "AdjustmentsMember", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementofcomprehensiveincomelossTable", "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementsoffinancialpositionTable" ], "xbrltype": "domainItemType" }, "xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities.", "label": "AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities", "terseLabel": "Adjustments to reconcile loss to net cash used in operating activities (a)" } } }, "localname": "AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "xtlb_AmericanDepositorySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AmericanDepositorySharesMember", "terseLabel": "American Depository Shares [Member]" } } }, "localname": "AmericanDepositorySharesMember", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/SubsequentEventsDetails", "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "domainItemType" }, "xtlb_AsRestatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AsRestatedMember", "terseLabel": "As restated [Member]" } } }, "localname": "AsRestatedMember", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementofcomprehensiveincomelossTable", "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementsoffinancialpositionTable" ], "xbrltype": "domainItemType" }, "xtlb_BNonCashActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BNonCashActivitiesAbstract", "terseLabel": "(b) Non-cash activities:" } } }, "localname": "BNonCashActivitiesAbstract", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "xtlb_BasicAndDilutedEarningsLossPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]", "label": "BasicAndDilutedEarningsLossPerShare", "terseLabel": "Basic and diluted loss per share (in U.S. dollars): (in Dollars per share)", "verboseLabel": "Basic and diluted earnings (loss) per share (in U.S. dollars) (in Dollars per share)" } } }, "localname": "BasicAndDilutedEarningsLossPerShare", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement", "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementofcomprehensiveincomelossTable" ], "xbrltype": "perShareItemType" }, "xtlb_CanndocLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Canndoc Ltd [Member]", "label": "CanndocLtdMember", "terseLabel": "Canndoc Ltd [Member]" } } }, "localname": "CanndocLtdMember", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/TransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ChangesInOperatingAssetAndLiabilityItemsAbstract", "terseLabel": "Changes in operating asset and liability items:" } } }, "localname": "ChangesInOperatingAssetAndLiabilityItemsAbstract", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "xtlb_Commitments": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments", "terseLabel": "Accounts payable" } } }, "localname": "Commitments", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "xtlb_CondensedStatementsOfChangesInEquityUnauditedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Changes in Equity (Unaudited) [Abstract]" } } }, "localname": "CondensedStatementsOfChangesInEquityUnauditedAbstract", "nsuri": "http://xtlb.com/20210630", "xbrltype": "stringItemType" }, "xtlb_CurrentMarketableSecurities": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.", "label": "CurrentMarketableSecurities", "terseLabel": "Marketable securities \u2013 InterCure Ltd" } } }, "localname": "CurrentMarketableSecurities", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "xtlb_DateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DateAxis", "terseLabel": "Date [Axis]" } } }, "localname": "DateAxis", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingwarrantsTable" ], "xbrltype": "stringItemType" }, "xtlb_DateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Date [Domain]" } } }, "localname": "DateDomain", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingwarrantsTable" ], "xbrltype": "domainItemType" }, "xtlb_DepositaryShareAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DepositaryShareAxis", "terseLabel": "Depositary Share [Axis]" } } }, "localname": "DepositaryShareAxis", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/SubsequentEventsDetails", "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "xtlb_DepositaryShareDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DepositaryShare [Domain]" } } }, "localname": "DepositaryShareDomain", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/SubsequentEventsDetails", "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "domainItemType" }, "xtlb_DescriptionOfExpectedVolatilityShareOptionGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.", "label": "DescriptionOfExpectedVolatilityShareOptionGranted", "terseLabel": "Expected volatility" } } }, "localname": "DescriptionOfExpectedVolatilityShareOptionGranted", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "percentItemType" }, "xtlb_DescriptionOfRiskFreeInterestsRateShareOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]", "label": "DescriptionOfRiskFreeInterestsRateShareOptionsGranted", "terseLabel": "Risk-free interest rate" } } }, "localname": "DescriptionOfRiskFreeInterestsRateShareOptionsGranted", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "percentItemType" }, "xtlb_DescriptionOfWarrantsExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of warrants shall be exercisable.", "label": "DescriptionOfWarrantsExercisable", "terseLabel": "Description of warrants exercisable" } } }, "localname": "DescriptionOfWarrantsExercisable", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "xtlb_DisclosureOfBasisOfPreparationOfFinancialStatementsTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of basis of preparation of financial statements [text block] [Abstract]" } } }, "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsTextBlockAbstract", "nsuri": "http://xtlb.com/20210630", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfConsolidatedStatementOfComprehensiveIncomelossTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DisclosureOfConsolidatedStatementOfComprehensiveIncomelossTableTextBlock", "terseLabel": "Schedule of impact on the consolidated statement of comprehensive income (loss)" } } }, "localname": "DisclosureOfConsolidatedStatementOfComprehensiveIncomelossTableTextBlock", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/RestatementTables" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfDetailedInformationAboutConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DisclosureOfDetailedInformationAboutConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock", "terseLabel": "Schedule of impact on the consolidated statements of financial position" } } }, "localname": "DisclosureOfDetailedInformationAboutConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/RestatementTables" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfEventsAfterReportingPeriodTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of events after reporting period [text block] [Abstract]" } } }, "localname": "DisclosureOfEventsAfterReportingPeriodTextBlockAbstract", "nsuri": "http://xtlb.com/20210630", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfGeneralHedgeAccountingTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of general hedge accounting [text block] [Abstract]" } } }, "localname": "DisclosureOfGeneralHedgeAccountingTextBlockAbstract", "nsuri": "http://xtlb.com/20210630", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfMarketableSecuritiesExplanatoryAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Marketable Securities Explanatory [Abstract]" } } }, "localname": "DisclosureOfMarketableSecuritiesExplanatoryAbstract", "nsuri": "http://xtlb.com/20210630", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfMarketableSecuritiesExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for marketable securities.", "label": "DisclosureOfMarketableSecuritiesExplanatoryTextBlock", "terseLabel": "MARKETABLE SECURITIES \u2013 InterCure Ltd" } } }, "localname": "DisclosureOfMarketableSecuritiesExplanatoryTextBlock", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/MarketableSecuritiesInterCureLtd" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfRelatedPartyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of related party [text block] [Abstract]" } } }, "localname": "DisclosureOfRelatedPartyTextBlockAbstract", "nsuri": "http://xtlb.com/20210630", "xbrltype": "stringItemType" }, "xtlb_DisclosureOfRestatementtextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of restatement.", "label": "DisclosureOfRestatementtextBlock", "terseLabel": "RESTATEMENT" } } }, "localname": "DisclosureOfRestatementtextBlock", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/Restatement" ], "xbrltype": "textBlockItemType" }, "xtlb_DisclosureOfRestatementtextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Restatementtext Block [Abstract]" } } }, "localname": "DisclosureOfRestatementtextBlockAbstract", "nsuri": "http://xtlb.com/20210630", "xbrltype": "stringItemType" }, "xtlb_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://xtlb.com/20210630", "xbrltype": "stringItemType" }, "xtlb_ExercisePriceInUSDperWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share.", "label": "ExercisePriceInUSDperWarrant", "terseLabel": "Exercise price in USD (per warrant) (in Dollars per share)" } } }, "localname": "ExercisePriceInUSDperWarrant", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingwarrantsTable" ], "xbrltype": "perShareItemType" }, "xtlb_ExpectedDividendAsPercentageShareOptionGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted.", "label": "ExpectedDividendAsPercentageShareOptionGranted", "terseLabel": "Dividend yield" } } }, "localname": "ExpectedDividendAsPercentageShareOptionGranted", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "percentItemType" }, "xtlb_ExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expiration date.", "label": "ExpirationDate", "terseLabel": "Expiration date" } } }, "localname": "ExpirationDate", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingwarrantsTable" ], "xbrltype": "dateItemType" }, "xtlb_FebruarySeventeenTwoThousandSeventeenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FebruarySeventeenTwoThousandSeventeenMember", "terseLabel": "February 17, 2017 [Member]" } } }, "localname": "FebruarySeventeenTwoThousandSeventeenMember", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingwarrantsTable" ], "xbrltype": "domainItemType" }, "xtlb_GainsFromExchangeRateDifferencesOnCashAndCashEquivalents": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gains from exchange rate differences on cash and cash equivalents.", "label": "GainsFromExchangeRateDifferencesOnCashAndCashEquivalents", "negatedLabel": "Gains from exchange rate differences on cash and cash equivalents" } } }, "localname": "GainsFromExchangeRateDifferencesOnCashAndCashEquivalents", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "xtlb_GeneralLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General [Abstract]" } } }, "localname": "GeneralLineItems", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/General" ], "xbrltype": "stringItemType" }, "xtlb_GeneralTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General [Table]" } } }, "localname": "GeneralTable", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/General" ], "xbrltype": "stringItemType" }, "xtlb_GrossFundRaised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of gross fund raised.", "label": "GrossFundRaised", "terseLabel": "Gross funds raised (in Dollars)" } } }, "localname": "GrossFundRaised", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "monetaryItemType" }, "xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract", "terseLabel": "Income and expenses not involving operating cash flows:" } } }, "localname": "IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "xtlb_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in prepaid expenses and other current assets.", "label": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets", "negatedLabel": "Decrease (increase) in prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "xtlb_InterestIncome": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "It represents of interest income.", "label": "InterestIncome", "negatedLabel": "Interest income" } } }, "localname": "InterestIncome", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "xtlb_IssuanceDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance date.", "label": "IssuanceDate", "terseLabel": "Issuance date" } } }, "localname": "IssuanceDate", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingwarrantsTable" ], "xbrltype": "dateItemType" }, "xtlb_IssuanceOfOfferingDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of offering date.", "label": "IssuanceOfOfferingDate", "terseLabel": "Issuance of offering date" } } }, "localname": "IssuanceOfOfferingDate", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "xtlb_IssuedOfOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of ordinary shares issued.", "label": "IssuedOfOrdinaryShares", "terseLabel": "Issue of ordinary shares" } } }, "localname": "IssuedOfOrdinaryShares", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "xtlb_MarchSevenTwoThousandAndSeventeenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MarchSevenTwoThousandAndSeventeenMember", "terseLabel": "March 7, 2017 [Member]" } } }, "localname": "MarchSevenTwoThousandAndSeventeenMember", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingwarrantsTable" ], "xbrltype": "domainItemType" }, "xtlb_MarketableSecuritiesInterCureLtdLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Marketable Securities - InterCure Ltd [Abstract]" } } }, "localname": "MarketableSecuritiesInterCureLtdLineItems", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/MarketableSecuritiesInterCureLtd" ], "xbrltype": "stringItemType" }, "xtlb_MarketableSecuritiesInterCureLtdTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Marketable Securities \u2013 InterCure Ltd [Table]" } } }, "localname": "MarketableSecuritiesInterCureLtdTable", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/MarketableSecuritiesInterCureLtd" ], "xbrltype": "stringItemType" }, "xtlb_NonCurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NonCurrentLiabilitiesAbstract", "terseLabel": "NON-CURRENT LIABILITIES:" } } }, "localname": "NonCurrentLiabilitiesAbstract", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "xtlb_NonadjustingEventMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NonadjustingEventMember", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "NonadjustingEventMember", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "xtlb_NoncurrentWarrants": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non current warrants.", "label": "NoncurrentWarrants", "terseLabel": "Warrants" } } }, "localname": "NoncurrentWarrants", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "xtlb_NumberOfADSsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of ADSs issued.", "label": "NumberOfADSsIssued", "terseLabel": "Number of ADSs issued" } } }, "localname": "NumberOfADSsIssued", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/SubsequentEventsDetails", "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "xtlb_NumberOfInvestors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of personnel investors.", "label": "NumberOfInvestors", "terseLabel": "Number of investors" } } }, "localname": "NumberOfInvestors", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/SubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "xtlb_NumberOfOrdinarySharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of ordinary shares issued.", "label": "NumberOfOrdinarySharesIssued", "terseLabel": "Number of ordinary shares issued" } } }, "localname": "NumberOfOrdinarySharesIssued", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "xtlb_NumberOfSharesExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares exercisable.", "label": "NumberOfSharesExercisable", "terseLabel": "Number of shares exercisable" } } }, "localname": "NumberOfSharesExercisable", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingwarrantsTable" ], "xbrltype": "sharesItemType" }, "xtlb_OfferingDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Offering date.", "label": "OfferingDate", "terseLabel": "Offering date" } } }, "localname": "OfferingDate", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "xtlb_OtherFinancialExpensesincomeLoss": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "It represents of other financial expenses income loss.", "label": "OtherFinancialExpensesincomeLoss", "negatedLabel": "Other financial expenses (income)" } } }, "localname": "OtherFinancialExpensesincomeLoss", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "xtlb_PercentageOfHoldingShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of holding shares.", "label": "PercentageOfHoldingShare", "terseLabel": "Percentage of shares hold" } } }, "localname": "PercentageOfHoldingShare", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/MarketableSecuritiesInterCureLtdDetails" ], "xbrltype": "percentItemType" }, "xtlb_PreviouslyReportedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PreviouslyReportedMember", "terseLabel": "As previously reported [Member]" } } }, "localname": "PreviouslyReportedMember", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementofcomprehensiveincomelossTable", "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementsoffinancialpositionTable" ], "xbrltype": "domainItemType" }, "xtlb_ProportionOfOwnershipInterestInInterCureLtd": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The proportion of ownership interest in InterCure Ltd.", "label": "ProportionOfOwnershipInterestInInterCureLtd", "terseLabel": "Company's share in the shares of InterCure Ltd" } } }, "localname": "ProportionOfOwnershipInterestInInterCureLtd", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/TransactionsWithRelatedPartiesDetails" ], "xbrltype": "percentItemType" }, "xtlb_RentPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent paid during the period.", "label": "RentPayments", "terseLabel": "Rent payments (in Dollars)" } } }, "localname": "RentPayments", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/TransactionsWithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "xtlb_RestatementDetailsScheduleofimpactontheconsolidatedstatementofcomprehensiveincomelossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restatement (Details) - Schedule of impact on the consolidated statement of comprehensive income (loss) [Line Items]" } } }, "localname": "RestatementDetailsScheduleofimpactontheconsolidatedstatementofcomprehensiveincomelossLineItems", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementofcomprehensiveincomelossTable" ], "xbrltype": "stringItemType" }, "xtlb_RestatementDetailsScheduleofimpactontheconsolidatedstatementofcomprehensiveincomelossTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restatement (Details) - Schedule of impact on the consolidated statement of comprehensive income (loss) [Table]" } } }, "localname": "RestatementDetailsScheduleofimpactontheconsolidatedstatementofcomprehensiveincomelossTable", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementofcomprehensiveincomelossTable" ], "xbrltype": "stringItemType" }, "xtlb_RestatementDetailsScheduleofimpactontheconsolidatedstatementsoffinancialpositionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restatement (Details) - Schedule of impact on the consolidated statements of financial position [Line Items]" } } }, "localname": "RestatementDetailsScheduleofimpactontheconsolidatedstatementsoffinancialpositionLineItems", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementsoffinancialpositionTable" ], "xbrltype": "stringItemType" }, "xtlb_RestatementDetailsScheduleofimpactontheconsolidatedstatementsoffinancialpositionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restatement (Details) - Schedule of impact on the consolidated statements of financial position [Table]" } } }, "localname": "RestatementDetailsScheduleofimpactontheconsolidatedstatementsoffinancialpositionTable", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementsoffinancialpositionTable" ], "xbrltype": "stringItemType" }, "xtlb_RevaluationOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows", "weight": -1.0 }, "http://xtlb.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revaluable of marketable securites.", "label": "RevaluationOfMarketableSecurities", "negatedLabel": "Revaluation of marketable securities - InterCure Ltd", "terseLabel": "Revaluation of marketable securities - InterCure Ltd" } } }, "localname": "RevaluationOfMarketableSecurities", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow", "http://xtlb.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "xtlb_RevaluationOfWarrantsToPurchase": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Revaluation of warrants to purchase .", "label": "RevaluationOfWarrantsToPurchase", "terseLabel": "Revaluation of warrants to purchase ADS\u2019s" } } }, "localname": "RevaluationOfWarrantsToPurchase", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "xtlb_RevaluationOfWarrantsToPurchaseAds": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revaluation of warrants to purchase ads.", "label": "RevaluationOfWarrantsToPurchaseAds", "terseLabel": "Revaluation of warrants to purchase ADS\u2019s" } } }, "localname": "RevaluationOfWarrantsToPurchaseAds", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ConsolidatedIncomeStatement", "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementofcomprehensiveincomelossTable" ], "xbrltype": "monetaryItemType" }, "xtlb_RevisionOfPriorPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by adjustment to previously issued financial statements.", "label": "RevisionOfPriorPeriodAxis", "terseLabel": "Revision of Prior Period [Axis]" } } }, "localname": "RevisionOfPriorPeriodAxis", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementofcomprehensiveincomelossTable", "http://xtlb.com/role/ScheduleofimpactontheconsolidatedstatementsoffinancialpositionTable" ], "xbrltype": "stringItemType" }, "xtlb_ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of compensation to key management personnel for employee services [Abstract]" } } }, "localname": "ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract", "nsuri": "http://xtlb.com/20210630", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfFinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of financial instruments [Abstract]" } } }, "localname": "ScheduleOfFinancialInstrumentsAbstract", "nsuri": "http://xtlb.com/20210630", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfImpactOnTheConsolidatedStatementOfComprehensiveIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of impact on the consolidated statement of comprehensive income (loss) [Abstract]" } } }, "localname": "ScheduleOfImpactOnTheConsolidatedStatementOfComprehensiveIncomeLossAbstract", "nsuri": "http://xtlb.com/20210630", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfImpactOnTheConsolidatedStatementsOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of impact on the consolidated statements of financial position [Abstract]" } } }, "localname": "ScheduleOfImpactOnTheConsolidatedStatementsOfFinancialPositionAbstract", "nsuri": "http://xtlb.com/20210630", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfOutstandingWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of outstanding warrants [Abstract]" } } }, "localname": "ScheduleOfOutstandingWarrantsAbstract", "nsuri": "http://xtlb.com/20210630", "xbrltype": "stringItemType" }, "xtlb_ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share based payments award stock warrats valuation assumptions.", "label": "ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock", "terseLabel": "Schedule of warrants valuation assumptions of investors' warrants" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "xtlb_ScheduleOfTheOutstandingWarrantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of schedule of the outstanding warrants table.", "label": "ScheduleOfTheOutstandingWarrantsTableTextBlock", "terseLabel": "Schedule of outstanding warrants" } } }, "localname": "ScheduleOfTheOutstandingWarrantsTableTextBlock", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "xtlb_ScheduleOfWarrantsValuationAssumptionsOfInvestorsWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of warrants valuation assumptions of investors' warrants [Abstract]" } } }, "localname": "ScheduleOfWarrantsValuationAssumptionsOfInvestorsWarrantsAbstract", "nsuri": "http://xtlb.com/20210630", "xbrltype": "stringItemType" }, "xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based payment transactions to employees and non-employees.", "label": "ShareBasedPaymentTransactionsToEmployeesAndNonEmployees", "terseLabel": "Share-based payment transactions to employees and non-employees" } } }, "localname": "ShareBasedPaymentTransactionsToEmployeesAndNonEmployees", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "xtlb_SubsequentEventsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Line Items]" } } }, "localname": "SubsequentEventsDetailsLineItems", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "xtlb_SubsequentEventsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "localname": "SubsequentEventsDetailsTable", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "xtlb_SubsequentEventsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsLineItems", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/SubsequentEvents" ], "xbrltype": "stringItemType" }, "xtlb_SubsequentEventsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Table]" } } }, "localname": "SubsequentEventsTable", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/SubsequentEvents" ], "xbrltype": "stringItemType" }, "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows": { "auth_ref": [], "calculation": { "http://xtlb.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total amount of income and expenses not involving cash flows", "label": "TotalIncomeAndExpensesNotInvolvingCashFlows", "totalLabel": "Net income and expenses not involving cash flows" } } }, "localname": "TotalIncomeAndExpensesNotInvolvingCashFlows", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "xtlb_TransactionsWithRelatedPartiesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Transactions with Related Parties [Abstract]" } } }, "localname": "TransactionsWithRelatedPartiesDetailsLineItems", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/TransactionsWithRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "xtlb_TransactionsWithRelatedPartiesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Transactions With Related Parties (Details) [Table]" } } }, "localname": "TransactionsWithRelatedPartiesDetailsTable", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/TransactionsWithRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "xtlb_TransactionsWithRelatedPartiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of Transactions with Related Parties [Abstract]" } } }, "localname": "TransactionsWithRelatedPartiesLineItems", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/TransactionsWithRelatedParties" ], "xbrltype": "stringItemType" }, "xtlb_TransactionsWithRelatedPartiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Transactions With Related Parties [Table]" } } }, "localname": "TransactionsWithRelatedPartiesTable", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/TransactionsWithRelatedParties" ], "xbrltype": "stringItemType" }, "xtlb_WarrantsAtFairValueOfExplanatoryAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants At Fair Value Of Explanatory [Abstract]" } } }, "localname": "WarrantsAtFairValueOfExplanatoryAbstract", "nsuri": "http://xtlb.com/20210630", "xbrltype": "stringItemType" }, "xtlb_WarrantsAtFairValueOfExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for warrants at fair value of explanatory.", "label": "WarrantsAtFairValueOfExplanatoryTextBlock", "terseLabel": "WARRANTS" } } }, "localname": "WarrantsAtFairValueOfExplanatoryTextBlock", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/Warrants" ], "xbrltype": "textBlockItemType" }, "xtlb_WarrantsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants (Details) [Line Items]" } } }, "localname": "WarrantsDetailsLineItems", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "xtlb_WarrantsDetailsScheduleofoutstandingwarrantsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants (Details) - Schedule of outstanding warrants [Line Items]" } } }, "localname": "WarrantsDetailsScheduleofoutstandingwarrantsLineItems", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingwarrantsTable" ], "xbrltype": "stringItemType" }, "xtlb_WarrantsDetailsScheduleofoutstandingwarrantsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants (Details) - Schedule of outstanding warrants [Table]" } } }, "localname": "WarrantsDetailsScheduleofoutstandingwarrantsTable", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingwarrantsTable" ], "xbrltype": "stringItemType" }, "xtlb_WarrantsDetailsScheduleofwarrantsvaluationassumptionsofinvestorswarrantsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants (Details) - Schedule of warrants valuation assumptions of investors' warrants [Line Items]" } } }, "localname": "WarrantsDetailsScheduleofwarrantsvaluationassumptionsofinvestorswarrantsLineItems", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "stringItemType" }, "xtlb_WarrantsDetailsScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants (Details) - Schedule of warrants valuation assumptions of investors' warrants [Table]" } } }, "localname": "WarrantsDetailsScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofwarrantsvaluationassumptionsofinvestorswarrantsTable" ], "xbrltype": "stringItemType" }, "xtlb_WarrantsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants (Details) [Table]" } } }, "localname": "WarrantsDetailsTable", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "xtlb_WarrantsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued.", "label": "WarrantsIssued", "terseLabel": "Warrants issued" } } }, "localname": "WarrantsIssued", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "xtlb_WarrantsOutstandingToPurchaseADSs": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants outstanding to purchase.", "label": "WarrantsOutstandingToPurchaseADSs", "terseLabel": "Warrants outstanding to purchase ADSs" } } }, "localname": "WarrantsOutstandingToPurchaseADSs", "nsuri": "http://xtlb.com/20210630", "presentation": [ "http://xtlb.com/role/ScheduleofoutstandingwarrantsTable" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2021-03-24" }, "r1": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard", "URIDate": "2021-03-24" }, "r10": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2021-03-24" }, "r11": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_d&doctype=Standard", "URIDate": "2021-03-24" }, "r12": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2021-03-24" }, "r13": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard", "URIDate": "2021-03-24" }, "r14": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r15": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard", "URIDate": "2021-03-24" }, "r16": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2021-03-24" }, "r17": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r18": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r19": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2021-03-24" }, "r2": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "104", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_104&doctype=Standard", "URIDate": "2021-03-24" }, "r20": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_b&doctype=Standard", "URIDate": "2021-03-24" }, "r21": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2021-03-24" }, "r22": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard", "URIDate": "2021-03-24" }, "r23": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard", "URIDate": "2021-03-24" }, "r24": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r25": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Paragraph": "21", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_21_b&doctype=Standard", "URIDate": "2021-03-24" }, "r26": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Paragraph": "21", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_21&doctype=Standard", "URIDate": "2021-03-24" }, "r27": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2021-03-24" }, "r28": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2021-03-24" }, "r29": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18A&doctype=Standard", "URIDate": "2021-03-24" }, "r3": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2021-03-24" }, "r30": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard", "URIDate": "2021-03-24" }, "r31": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Section": "Disclosures", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2021-03-24" }, "r32": { "Clause": "v", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_v&doctype=Standard", "URIDate": "2021-03-24" }, "r33": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r34": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2021-03-24" }, "r35": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2021-03-24" }, "r36": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24" }, "r37": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard", "URIDate": "2021-03-24" }, "r38": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2021-03-24" }, "r39": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard", "URIDate": "2021-03-24" }, "r4": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r40": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2021-03-24" }, "r41": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2021-03-24" }, "r42": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2021-03-24" }, "r43": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard", "URIDate": "2021-03-24" }, "r44": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "25", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard", "URIDate": "2021-03-24" }, "r45": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "28", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard", "URIDate": "2021-03-24" }, "r46": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "31", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard", "URIDate": "2021-03-24" }, "r47": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24" }, "r48": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2021-03-24" }, "r49": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI", "URIDate": "2021-03-24" }, "r5": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2021-03-24" }, "r50": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2021-03-24" }, "r51": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2021-03-24" }, "r52": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r53": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r54": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r55": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r56": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r57": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r58": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r59": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2021-03-24" }, "r6": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard", "URIDate": "2021-03-24" }, "r60": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2021-03-24" }, "r61": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2021-03-24" }, "r62": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "B6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r63": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "IE63", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r64": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "14", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2021-03-24" }, "r65": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2021-03-24" }, "r66": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "31", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard", "URIDate": "2021-03-24" }, "r67": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35K", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2021-03-24" }, "r68": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24" }, "r69": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Section": "Hedge accounting", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g21A-24G_TI", "URIDate": "2021-03-24" }, "r7": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard", "URIDate": "2021-03-24" }, "r70": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard", "URIDate": "2021-03-24" }, "r71": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2021-03-24" }, "r72": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2021-03-24" }, "r73": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2021-03-24" }, "r74": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard", "URIDate": "2021-03-24" }, "r75": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2021-03-24" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r8": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2021-03-24" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r85": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r9": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117&doctype=Standard", "URIDate": "2021-03-24" } }, "version": "2.1" }